Compare iShares MSCI France ETF (EWQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Sanofi SA — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.91M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 287.6× iShares MSCI France ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Sanofi SA for 94 Days on average.
| EWQ | SNY | |
|---|---|---|
Market Cap | $330.91M | $95.18B |
Volume | 556,654 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $52.34 |
52-Week Low | $41.32 | $39.51 |
Typical Hold Time | 55 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.52 with a slight 0.44% daily gain, though technical indicators show a bearish bias with moving averages signaling strong selling pressure. The stock faces mixed sentiment with oscillators suggesting potential oversold conditions while European market uncertainties create headwinds. Recent news highlights ECB rate hikes and energy-driven inflation concerns affecting European equities.
The stock's outlook remains cautious with technical weakness offset by potential oversold bounce opportunities. Key risks include European economic sentiment deterioration and persistent inflation pressures, while the absence of fundamental data requires careful monitoring of upcoming financial disclosures for valuation clarity.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
